The Philippines is currently facing a sharp rise in HIV cases, with a staggering 500% increase reported among the youth.

In 2021, approval of cabotegravir (Apretude) as the first long-acting PrEP option provided patients an option to move from ...

The PURPOSE trials illuminated the ways in which lenacapavir could be used as a means of pre-exposure prophylaxis effectively, but also featured several adverse events.

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

Eight times more young Americans are taking antiretroviral meds to protect them from HIV infection than a decade ago, a new ...

Updated CDC guidelines on PEP after nonoccupational HIV exposure address newer ART agents and clinical considerations for patients with a history of long-acting ART.